期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

罗格列酮治疗2型糖尿病的机制及临床疗效 被引量：31

Mechanism and clinical efficacy of rosiglitazone in treating type 2 diabetes
下载PDF
导出
摘要 2型糖尿病的根本病因是胰岛素抵抗和B细胞功能损害。传统的治疗方法不能针对糖尿病病因 ,因而无法实现血糖的长期控制。罗格列酮则能显著降低胰岛素抵抗并改善B细胞功能 ,从而持久稳定地控制糖尿病。 The basic cause of type 2 diabetes is the insulin resistance and the beta cells dysfunctional. Rosiglitazone can improve insulin sensitivity, protect the function of pancreatic B cells and steadily control the blood glucose. This article explains the mechanism and clinical efficacy of rosiglitazone in treating type 2 diabetes mellitus.
作者 朱耀国 任叶慧 姜军权
机构地区 中国人民解放军
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2003年第12期751-753,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 降血糖药 罗格列酮 糖尿病 非胰岛素依赖型 药物评价 药理学 hypoglycemic agents rosiglitazone diabetes mellitus, non insulin dependent drug evaluation pharmacology
分类号 R587.1 [医药卫生—内分泌] R977.15 [医药卫生—药品]
  • 相关文献

参考文献18

  • 1[1]World Health Organization. The World Health Report: Conquering suffering, enriching humanity[M]. Geneva: WHO,1997.6.
  • 2[2]World Health Organization. The World Health Report: Life in the 21st century, a vision for all[M]. Geneva:WHO, 1998.5.
  • 3[3]SALTIEL AR, OLEFSKY JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes[J]. Diabetes,1996,45(12):1661-1669.
  • 4[4]HARING HU, MEHNERT H. Pathogenesis of type 2(non-insulin-dependent) diabetes mellitus:candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle[J]. Diabetologia,1993,36(3):176-182.
  • 5[5]UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. Lancet,1998,352(9131):837-853.
  • 6[6]SPIEGELMAN BM. PPAR-gamma:adipogenic regulator and thiazolidinedione receptor[J]. Diabetes,1998,47(4):507-514.
  • 7[7]YOUNG PW, CAWTHORNE MA, COYLE PJ, et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling[J]. Diabetes,1995,44(9):1087-1092.
  • 8[8]LISTER CA. Rosiglitazone increases pancreatic islet area, number and insulin content, but not insulin gene expression[J]. Diabetologia,1998,41 Suppl 1: A660.
  • 9[9]SMITH S, BOAM D, BRETHERTON-WATT D, et al. Rosiglitazone increases pancreatic islet area, density and insulin content, but not insulin gene expression[J]. Diabetes,1998, 47 Suppl 1:A18.
  • 10[10]FINEGOOD DT. The PPAP γ agonist rosiglitazone decreases net loss of pancreatic β-cell mass in Zucker diabetic fatty rats[J]. Diabetes,1999,48 Suppl 1:A237.

同被引文献240

引证文献31

二级引证文献75

中国新药与临床杂志
2003年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部